VASCULAR TISSUE ANGIOTENSINII & ENDOTHELIAL DYSFUNCTION IN UNCOMPLICATED OBESITY

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。腰围超重与血管功能不佳和心血管风险增加有关。然而，其机制尚不清楚。体内一种名为血管紧张素原II的物质可能起到了一定作用。通过使用一种名为valsartan的药物阻断血管紧张素原II的产生，18-50岁腹围超标但其他方面健康的人的血管功能可能会得到改善。采用肱动脉血流介导的扩张、前臂容积图、皮肤激光多普勒血流和计算机动脉脉搏波分析来研究血管的反应。受试者将在不同的时间随机服用valsartan和安慰剂，以确定坎地沙坦是否改善血管功能。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Excess weight around the waist is associated with poor blood vessel function and increased cardiovascular risk. However, the mechanism is unclear. A substance in the body called angiotensinogen II may play a role. By blocking the production of angiotensinogen II with a medication called valsartan, blood vessel function may be improved in people ages 18-50 who have excess abdominal girth and are otherwise healthy. Brachial artery flow-mediated dilatation, forearm plethysmography, cutaneous laser doppler blood flow and computerized arterial pulse waveform analysis will be used to study the responses of the blood vessels. Subjects will be randomly given both valsartan and placebo at different times to determine if candesartan improves blood vessel function.